215 related articles for article (PubMed ID: 17034041)
1. Ligand-supported homology modeling of the human angiotensin II type 1 (AT(1)) receptor: insights into the molecular determinants of telmisartan binding.
Patny A; Desai PV; Avery MA
Proteins; 2006 Dec; 65(4):824-42. PubMed ID: 17034041
[TBL] [Abstract][Full Text] [Related]
2. Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model.
Lescot E; Sopkova-de Oliveira Santos J; Colloc'h N; Rodrigo J; Milazzo-Segalas I; Bureau R; Rault S
Proteins; 2008 Oct; 73(1):173-84. PubMed ID: 18409194
[TBL] [Abstract][Full Text] [Related]
3. Ligand binding determinants for angiotensin II type 1 receptor from computer simulations.
Matsoukas MT; Cordomí A; Ríos S; Pardo L; Tselios T
J Chem Inf Model; 2013 Nov; 53(11):2874-83. PubMed ID: 24090110
[TBL] [Abstract][Full Text] [Related]
4. Structural determinants of subtype selectivity and functional activity of angiotensin II receptors.
Sallander J; Wallinder C; Hallberg A; Åqvist J; Gutiérrez-de-Terán H
Bioorg Med Chem Lett; 2016 Feb; 26(4):1355-9. PubMed ID: 26810314
[TBL] [Abstract][Full Text] [Related]
5. Unique "delta lock" structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor.
Ohno K; Amano Y; Kakuta H; Niimi T; Takakura S; Orita M; Miyata K; Sakashita H; Takeuchi M; Komuro I; Higaki J; Horiuchi M; Kim-Mitsuyama S; Mori Y; Morishita R; Yamagishi S
Biochem Biophys Res Commun; 2011 Jan; 404(1):434-7. PubMed ID: 21130741
[TBL] [Abstract][Full Text] [Related]
6. Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling.
Bhuiyan MA; Ishiguro M; Hossain M; Nakamura T; Ozaki M; Miura S; Nagatomo T
Life Sci; 2009 Jul; 85(3-4):136-40. PubMed ID: 19446572
[TBL] [Abstract][Full Text] [Related]
7. Proposal of a new binding orientation for non-peptide AT1 antagonists: homology modeling, docking and three-dimensional quantitative structure-activity relationship analysis.
Tuccinardi T; Calderone V; Rapposelli S; Martinelli A
J Med Chem; 2006 Jul; 49(14):4305-16. PubMed ID: 16821790
[TBL] [Abstract][Full Text] [Related]
8. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.
Axe FU; Bembenek SD; Szalma S
J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.
Le MT; Pugsley MK; Vauquelin G; Van Liefde I
Br J Pharmacol; 2007 Aug; 151(7):952-62. PubMed ID: 17572702
[TBL] [Abstract][Full Text] [Related]
10. First pharmacophore model of CCR3 receptor antagonists and its homology model-assisted, stepwise virtual screening.
Jain V; Saravanan P; Arvind A; Mohan CG
Chem Biol Drug Des; 2011 May; 77(5):373-87. PubMed ID: 21284830
[TBL] [Abstract][Full Text] [Related]
11. Multiple templates-based homology modeling enhances structure quality of AT1 receptor: validation by molecular dynamics and antagonist docking.
Sokkar P; Mohandass S; Ramachandran M
J Mol Model; 2011 Jul; 17(7):1565-77. PubMed ID: 20924625
[TBL] [Abstract][Full Text] [Related]
12. Molecular modeling of A1 and A2A adenosine receptors: comparison of rhodopsin- and beta2-adrenergic-based homology models through the docking studies.
Yuzlenko O; Kieć-Kononowicz K
J Comput Chem; 2009 Jan; 30(1):14-32. PubMed ID: 18496794
[TBL] [Abstract][Full Text] [Related]
13. Prediction of the Human EP1 Receptor Binding Site by Homology Modeling and Molecular Dynamics Simulation.
Zare B; Madadkar-Sobhani A; Dastmalchi S; Mahmoudian M
Sci Pharm; 2011; 79(4):793-816. PubMed ID: 22145106
[TBL] [Abstract][Full Text] [Related]
14. Insights into AT1 receptor activation through AngII binding studies.
Matsoukas MT; Potamitis C; Plotas P; Androutsou ME; Agelis G; Matsoukas J; Zoumpoulakis P
J Chem Inf Model; 2013 Nov; 53(11):2798-811. PubMed ID: 24053563
[TBL] [Abstract][Full Text] [Related]
15. Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists.
Lavecchia A; Cosconati S; Novellino E
J Med Chem; 2005 Apr; 48(7):2480-92. PubMed ID: 15801838
[TBL] [Abstract][Full Text] [Related]
16. Molecular modeling studies on the human neuropeptide S receptor and its antagonists.
Dal Ben D; Antonini I; Buccioni M; Lambertucci C; Marucci G; Vittori S; Volpini R; Cristalli G
ChemMedChem; 2010 Mar; 5(3):371-83. PubMed ID: 20087922
[TBL] [Abstract][Full Text] [Related]
17. Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets?
Bissantz C; Bernard P; Hibert M; Rognan D
Proteins; 2003 Jan; 50(1):5-25. PubMed ID: 12471595
[TBL] [Abstract][Full Text] [Related]
18. Molecular modeling of histamine H3 receptor and QSAR studies on arylbenzofuran derived H3 antagonists.
Dastmalchi S; Hamzeh-Mivehroud M; Ghafourian T; Hamzeiy H
J Mol Graph Model; 2008 Jan; 26(5):834-44. PubMed ID: 17561422
[TBL] [Abstract][Full Text] [Related]
19. Molecular modeling of neurokinin B and tachykinin NK₃ receptor complex.
Ganjiwale AD; Rao GS; Cowsik SM
J Chem Inf Model; 2011 Nov; 51(11):2932-8. PubMed ID: 21913652
[TBL] [Abstract][Full Text] [Related]
20. 3D model for TM region of the AT-1 receptor in complex with angiotensin II independently validated by site-directed mutagenesis data.
Nikiforovich GV; Marshall GR
Biochem Biophys Res Commun; 2001 Sep; 286(5):1204-11. PubMed ID: 11527428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
